Registration - AACI 2004 Annual Meeting/CCAF Fall
for the AACI 2004 Annual Meeting/CCAF Fall 2004
Meeting in Chicago is available on the AACI
website. The combined meeting at The Peninsula
Chicago is scheduled for Sunday, October 24 to
Tuesday, October 26.
For more information, please contact
Shannon Hatch at firstname.lastname@example.org
or (412) 647-3844.
on-line by October 1,
2004 to qualify for the regular
registration rate (rates will increase after that
date). October 1 is also the deadline to make
hotel reservations at the conference rate of $230
per night. Please call the Peninsula Chicago at 1-866-288-8889
and request the room rate for the AACI/CCAF 2004
behalf of the AACI and CCAF Program Committees, we
look forward to seeing you in Chicago next month!
Presents Awards for Scientific Achievement and
|Distinguished Scientist Awardee
Stuart L. Schreiber, PhD
|Public Service Awardee
Ellen V. Sigal, PhD
|Special Recognition Awardee
Edwin A. Mirand, PhD
AACI will honor three individuals with
awards for scientific achievement and service at
the 2004 Annual Meeting in Chicago October 25-26.
AACI will present the AACI Distinguished
Scientist Award to Stuart L. Schreiber, PhD; the
AACI Public Service Award to Ellen V. Sigal, PhD;
and an AACI Special Recognition Award to Edwin A.
“Each year, AACI honors a distinguished
scientist for his or her outstanding contributions
to cancer research,” said Frank McCormick, PhD,
AACI Board member, annual meeting program chair,
and director of the University of California San
Francisco Comprehensive Cancer Center and Cancer
Research Institute. “AACI is acknowledging Dr.
Schreiber for his pioneering discoveries and
contributions to cancer research.”
Dr. Schreiber is the Morris Loeb Professor
and chair of the Department of Chemistry and
Chemical Biology at Harvard University and an
investigator a the Howard Hughes Medical
Dr. Sigal is the founder and chairperson
of Friends of Cancer Research. “The public
service award recognizes an individual who is
dedicated to advancing cancer research and who
supports programs that ease the burden of cancer
on Americans,” said AACI’s executive director
Barbara Duffy Stewart. “Ellen Sigal’s
leadership in mobilizing public support for cancer
research funding and her stewardship of major
education programs on key cancer related policy
issues has contributed significantly to our shared
vision and hope for a future without cancer.”
secretary-treasurer of AACI for many years, Ed
Mirand worked tirelessly to promote cancer centers
and cancer programs,” said Harold L. Moses, MD,
president of AACI. “Dr. Mirand’s work on
behalf of the cancer centers is exemplified by his
success in helping to mobilize cancer constituents
across the U.S. to support the 1971 National
Cancer Act.” Dr. Mirand is Emeritus Vice
President for Educational Affairs, Roswell Park
Cancer Institute. More >
AACI Elects Three
Members to Board of Directors
AACI has elected three new members to its
12-member Board of Directors.
Their three-year terms will commence at the
AACI 2004 Annual Meeting, October 24-26, in
The directors-elect are Kenneth H. Cowan,
MD, PhD, director, UNMC/Eppley
Cancer Center, University of Nebraska, Omaha; Judith C.
Gasson, PhD, director, Jonsson Comprehensive
Cancer Center at UCLA, Los Angeles; and George J.
Weiner, MD, director, Holden Comprehensive Cancer
Center at the University of Iowa, Iowa City.
Dr. Cowan has directed the Eppley Cancer
Center since 1999.
Before joining Eppley, Dr. Cowan served as
chief of the Medical Breast Cancer Section at the
National Cancer Institute (NCI). He
was appointed to the National Cancer Advisory
Board of NCI in 2002.
Dr. Cowan’s laboratory research involves
studies in drug resistance and the function of
tumor suppressor genes in breast cancer cells.
Dr. Gasson has directed the
Jonsson Comprehensive Cancer Center since 1995.
She is a professor
of medicine and biological chemistry in the UCLA
School of Medicine.
A molecular biologist, Dr. Gasson was
instrumental in purifying for the first time a
hormone-like substance, called GM-CSF, which
increases the speed of bone marrow cell
reproduction and shortens the time it takes cancer
patients to recover after bone marrow transplants.
Weiner is the C.E. Block Chair of Cancer Research
and a professor of internal medicine at the
University of Iowa.
His clinical and research interests focus
on the immunotherapy of leukemia and lymphoma.
Dr. Weiner chairs the State of Iowa
Comprehensive Cancer Control Consortium.
CCSG Guidelines Approved by NCAB
14, the National Cancer Advisory Board voted
to approve Interim Polices and Guidelines Relating
to the Cancer Center Support Grant (CCSG). These
Interim Guidelines can be found on the NCI website
at http://www3.cancer.gov/cancercenters/guide9_04.pdf and
will be implemented for CCSG submissions beginning
February 1, 2005. The Guidelines will become final
upon sign-off by the Office of Extramural Research
at the National Institutes of Health (NIH).
US House of Representatives approved legislation
on September 9 that would provide NIH with a FY
2005 appropriation of $28.44 billion, an increase
of approximately 2.3% over last year’s amount.
This legislation appropriates $4.87 billion to
NCI, which is 2.4% more than FY 2004’s numbers.
If this legislation is adopted, these would be the
smallest increases for NIH and NCI in nearly 20
September 15, the Senate Appropriations Committee
introduced legislation recommending an
appropriation of $28.9 billion for NIH and $4.894
million for NCI. Both Senate and House
Appropriations Committees will establish final
numbers in conference committee.
this month, AACI President, Harold L. Moses, MD,
AACI Executive Director, Barbara Duffy Stewart,
MPH, and colleagues from the National Coalition
for Cancer Research met with Members of Congress
and staff to discuss a number of issues
impacting the cancer community including FY 2005
appropriations, NIH reauthorization, stem cell
research, health information technologies,
Medicare oral anticancer drug coverage and
Medicare cancer care reimbursement.
discussions at the May Public Issues Committee
meeting, AACI is in the preliminary planning
stages of organizing a cancer center panel session
for Members of Congress and staff to be held
on Capitol Hill early next year. Plans include collaboration with
Friends of Cancer Research, the House Cancer
Caucus and the Senate Cancer Coalition.
from the Centers
The Cancer Center at Baylor College of
Medicine has named Dr. Kent Osborne acting
director. Dr. Osborne is director of the Breast
Center and the Tina and Dudley Sharp Chair in
Oncology at Baylor.
Dr. Osborne replaces Dr. Michael Lieberman,
who is director of a new research institute at The
Methodist Hospital, Houston. More >
The Commonwealth of Pennsylvania has
Awarded $10 Million to Fox Chase Cancer Center for
the first phase of a long-term expansion
expansion will start with a five-story Cancer
Research Pavilion. More >
Two international leaders in breast cancer
research and treatment, husband
and wife, have joined Fox Chase. Dr. Craig Jordan has
been named vice president and scientific director
for the medical science division and holds the new
Alfred G. Knudson Jr., MD, PhD, Chair in Cancer
Monica Morrow is chairman of surgical oncology at
Fox Chase and holds the G. Willing
"Wing" Pepper Chair in Cancer Research.
Tina Devery has been appointed the new
associate director for administration at the
Holden Comprehensive Cancer Center at the
University of Iowa.
Ms. Devery comes to Holden from Children's
Mercy Hospital, Kansas City, Mo. More
The Barbara Ann Karmanos Cancer Institute
plans to build a $47 million clinical cancer
center in downtown Detroit and acquire the Detroit
Medical Center’s Cancer Hospital assets. The new
partnership will further cement the research and
clinical affiliations of both organizations with
Wayne State University and its School of Medicine.
Q. Ping Dou, leader of the Prevention Program at
Karmanos Cancer Institute has received a $492,000
federal grant to fund groundbreaking research on a
new family of non-toxic anti-cancer drugs.
Dr. Dou will use the award from the U.S.
Department of Defense Breast Cancer Program to
study a group of synthetic, antibiotic-derived
drugs that are not toxic to human beings. More >
The Gynecologic Cancer Center
for the Study of Racial Disparities has received a
$2.1 million federal grant. The specialized center
is a collaboration between the Ohio State
University Comprehensive Cancer Center and Walter
Reed Army Medical Center that focuses on cancer
prevention strategies and the development of new
treatments for gynecologic cancers. More
Researchers in the OSU
Comprehensive Cancer Center have devised a new way
to understand how the immune system responds to
interferon alfa (IFN-a), a common treatment for
malignant melanoma that sometimes involves
debilitating side effects.
Dr. William Carson, director of clinical
research at OSU’s cancer center (OSUCCC) is
senior author of the study in the Journal of
the National Cancer Institute. More
Performing breast reconstruction surgery
at the time of mastectomy does not delay
post-operative chemotherapy for women with breast
cancer, according to a study by Dr. Richard Bold
and fellow researchers at the University of
California Davis Cancer Center. More
Thomas J. Kipps has been appointed as the holder
of the Evelyn and Edwin Tasch Chair in Cancer
Research in the University of California, San
Diego School of Medicine. Dr. Kipps is deputy
director for research at the Rebecca and John
Moores UCSD Cancer Center.
University of Pittsburgh Cancer Institute (UPCI)
has received a five-year, $10 million Specialized
Program of Research Excellence (SPORE) from the
National Cancer Institute to examine innovative
treatment strategies designed to improve survival
outcomes for patients with head and neck cancer.
This is the second SPORE awarded to UPCI - the
first was awarded to the cancer institute's Lung
Cancer Program in 2001 - and is one of only four
SPORE grants in head and neck cancer awarded
The University of Virginia Cancer Center
has appointed Dr. Geoffrey R. Weiss, deputy
director, and chief of the Division of
Hematology-Oncology. Dr. Weiss comes to Virginia
from the San Antonio Cancer Institute.
His recent research has focused on early
phase clinical trials of novel cancer therapies
for solid tumors, with a particular emphasis on
the use of cytokines.
to a Dana-Farber Cancer Institute and Brigham and
Women’s Hospital study, black men in the United
States are more likely than white men to be
diagnosed with advanced prostate cancer and have a
two-fold greater risk of dying from it, they are
significantly less likely to be screened for
prostate cancer. In a study involving more than
67,000 men age 65 years and older, the researchers
found that blacks were 35 percent less likely than
whites to undergo prostate-specific antigen (PSA)
testing. The findings are published in the Archives
of Internal Medicine. More
A part of the system that causes cells to
self-destruct when they are damaged or unneeded
has been harnessed to kill leukemia cells in mice,
say scientists at Dana Farber.
The study findings were published in the
September 3 issue of Science. More
Legislature and Governor of the State of North
authorized $180 million to build a
freestanding cancer hospital and office
complex for the UNC Health Care system and its UNC
Cancer Center. "This construction will
vastly expand and modernize
our cancer care and treatment facilities,
providing a first rate venue
for clinical research to match Lineberger Center
laboratory and headquarters
building and a new expansion for the UNC School of
Public Health," said Shelley
Earp, M.D., center director. The architectural
and functional planning of the new North Carolina
Cancer Hospital will be led
by Richard Goldberg, M.D., UNC Lineberger
associate director for
Clinical Research and chief of the oncology
service line for UNC Health
Care. The new construction is expected to be
completed in 2009.
Recruiting for Director for New Cancer Office
U. S. Food and Drug Administration (FDA) announced
plans in July to create a new oncology office,
called the Office of Oncology Drug Products (ODP),
to be housed in the Center for Drug Evaluation and
new office will be a consolidation of three
existing areas within CDER responsible for the
review of drugs and therapeutic biologics used to
diagnose, treat, and prevent cancer. The office
will also include drugs and certain therapeutic
biologics used in medical imaging, many of which
are used to detect, treat, or monitor cancer.
is conducting a broad national search to recruit a
director for the Office of Oncology Drug Products.
Please find the recruitment ad below. Interested
candidates are asked to submit curriculum vitae with
cover letter by November 15, 2004.
Director, Office of Oncology Drug Products
Supervisory Medical Officer
U.S. Department of Health and Human Services
Food and Drug Administration
The U.S. Food and Drug Administration
(FDA) is seeking a highly skilled and dedicated
individual to serve as Supervisory Medical Officer
and Director of the newly established Office of
Oncology Drug Products in the Center for Drug
Evaluation and Research’s (CDER) Office of New
Drugs (OND) in Rockville, Maryland. OND’s public
health mission ois to protect and enhance the
health of the public through the review and
evaluation of scientific data submitted by
pharmaceutical manufacturers in support of New
Drug Applications (NDAs), and Investigational New
Drug (IND) products, and Biological Licensing
The Director, Office of Oncology Drug
Products, will have overall responsibility for
regulatory oversight of product development for
cancer treatment and prevention, including drugs
and biological products, as well as their
evaluation for r marketing approval.
The Director will also have oversight of
hematologic agents, radiation protection agents,
medical imaging and radiographic products used in
the diagnosis, monitoring, and treatment of cancer
and other diseases.
In addition, the incumbent will oversee a
cross-cutting FDA Oncology Program, including an
Agency-wide Oncology Coordinating Committee to
ensure proactive and coordinated policies and
approaches to the development of products to treat
and prevent cancer.
A critical aspect of the Director’s
responsibility will be to develop and maintain
professional liaison with other government
agencies regarding policies related to cancer
(e.g., National Cancer Institute) and other
professional and consumer stakeholders.
This position offers the opportunity to
provide scientific and regulatory guidance at all
phases of oncology drug development, from clinical
trial design to evaluation of clinical trials data
submitted for product approval.
The Oncology Director will provide
leadership and guidance through a subordinate
staff of Division Directors.
The position involves working with the
pharmaceutical industry, individual investigators,
other government agencies and academia.
The position also offers opportunities to
work on a variety of initiatives including
development of risk management programs and
guidance documents for oncology drug development.
Applicants must have a Doctor of Medicine
or Doctor of Osteopathy degree from an accredited
medical school in the United States or Canada.
Graduates of foreign medical schools must
be certifies by the Education Commission for
Foreign Medical Graduates (ECFMG). Please submit a
copy of permanent ECFMG certification. Candidates
for Civil Service or U.S. Commissioned Corps must
be U.S. citizens.
The most desirable applicants will have
experience and expertise in clinical oncology,
drug or biological product development, clinical
trial design, conduct, and analysis. They will also have experience in the management of
professional in a highly complex environment and
strong interpersonal skills with an emphasis on
Postgraduate medical training in medical
oncology/hematology and clinical practice
experience in the diagnosis and treatment of
cancer is highly desirable.
For more information, contact the Office
of New Drugs/Program Management Team via email at:
Submit curriculum vitae by November 15,
2004 with cover letter indicating you are applying
to Source Code #0012-OND to:
U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Office of New Drugs
ATTN: Program Management Team
5515 Security Lane
Rockwall 2, Room 1039, HFD-022
Rockville, MD 20852
Member Institutions Recruiting for Leadership
Director of Administration
Hollings Cancer Center
Medical University of South Carolina
The Medical University of South Carolina,
College of Medicine and the Hollings Cancer Center
are recruiting for an Associate Director of
The successful applicant will work
collaboratively with the faculty and staff of the
Medical University of South Carolina to ensure the
continued development of the Hollings Cancer
Associate Director of Administration will provide
executive level assistance to the Director with
the design and implementation of goals and
objectives that will result in establishing the
Cancer Center as an NCI-designated center
recognized regionally and nationally and as a
renowned cancer research center of excellence and
Associate Director of Administration will be
responsible for and participate in the planning
and policy development involved in coordinating
the Cancer Center’s research and clinical
includes the management and supervision of the
programs and staff throughout the Cancer Center as
assigned by the Director.
The Associate Director will be involved in
the marketing, public relations, fundraising
initiatives associated with the programs of the
Center, and will work closely with other
University department administrators whose faculty
are intimately involved in providing the
multi-disciplinary cancer care and research.
Additionally, the Associate Director will
serve as a representative of the Cancer Center on
various committees and boards as necessary, as
well as for external physician groups and the
Associate Director for Administration reports to
the Cancer Center Director and has oversight
responsibility for the Cancer Center’s assigned
space, equipment, budgets, and information systems
associated with Hollings Cancer Center and its
Interested candidates should send a copy
of their resume and the names of three references
Andrew S. Kraft, MD
Director, Hollings Cancer Center
William H. Folk Chair in Experimental Oncology
86 Jonathan Lucas Street
P.O. Box 250955
Fax to 843-792-3200 or e-mail to email@example.com
Director for Administration
OU Cancer Center
University of Oklahoma
The associate director for administration is the
senior administrative and fiscal officer for the
OU Cancer Center, University of Oklahoma, and is a
key member of the senior leadership team.
The Center is a multidisciplinary organization
with a membership of 150+ faculty and other
academic staff from all seven OU schools
(Medicine, Pharmacy, Nursing, Dentistry, Public
Health, Allied Health Professions and the Graduate
School). Responsibilities of this position
include financial management; human resources
management; management information systems
development; organizational planning; space and
facilities management; program planning and
development; capital improvements; research,
education and training. Position develops,
recommends and implements administrative and
fiscal policies and procedures for the Center in
compliance with all University, NIH, federal and
state guidelines, and represents the Center's
interests to a wide range of extramural
constituents. As a member of many of the
Center's executive committees, participates in
senior-level policy formulation discussions,
specific projects, and short-, intermediate- and
long-range strategic planning for the overall
management of the Center's programs. Other
duties as required or assigned.
Required: An earned doctoral degree in cancer
Demonstrated research expertise and
scholarly publications. Minimum 5 years of
progressively responsible experience in
university, healthcare or equivalent
Significant experience in grant writing and
future grant writing is a prerequisite.
Excellent written and verbal communication,
interpersonal, organizational, and finance skills.
Proven leadership skills and ability to work
independently as well as function successfully as
a team member.
Please send curriculum vitae and the names of four
Howard Ozer MD, PhD
Chairperson, Search Committee
OU Cancer Center, University of Oklahoma
P.O. Box 26901, WP2080
Oklahoma City, OK 73190
University of Texas/M.D. Anderson Cancer Center
M.D. Anderson Cancer Center (MDACC) is
seeking a talented individual to provide
administrative coordination for its comprehensive
Cancer Center Support Grant (CCSG). MDACC holds the largest number of National Cancer Institute
(NCI) grants and the largest amount of NCI funding
among academic institutions.
The CCSG grant supports 19 programs and 19
The CCSG Administrator will coordinate,
analyze, and support all aspects of the CCSG.
Other duties include developing databases,
preparing budgets, initiating grant renewals,
writing grants, and coordinating all financial and
Applicants must have a minimum of a
Master’s degree in biology, chemistry, business,
or health administration. The successful candidate
must have five years experience in preparing
grants, developing budgets, and managing
Interested candidates please contact:
Robert Bast at firstname.lastname@example.org
Shetter at email@example.com or 713-792-7891